Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial

Ann Thorac Surg. 1999 Apr;67(4):994-1000. doi: 10.1016/s0003-4975(99)00062-4.

Abstract

Background: Heparin-coated circuits (HCCs) in low-risk cardiac patients who have coronary revascularization have a limited impact on postoperative outcome. In this prospective, randomized investigation, we studied high-risk patients who had cardiac operations with or without HCCs.

Methods: A total of 886 patients who had cardiac operations with cardiopulmonary bypass and at least one patient-related or procedure-related risk factor were enrolled in a multicenter study. They were randomly allocated to have cardiopulmonary bypass with Duraflo II HCCs (HCC group, n = 442) or conventional circuits (control group, n = 444). Postoperative outcome was investigated with respect to the occurrence of organ dysfunction.

Results: HCCs are associated with a shorter intensive care unit and postoperative hospital stay and with a lower rate of patients having a severely impaired clinical outcome (stay in intensive care unit for more than 5 days or death) (relative risk 0.66, p = 0.045). Lung dysfunction rate was significantly lower for the patients in HCC group affected by chronic obstructive pulmonary disease or who had mitral procedure (relative risk, respectively, 0.31, p = 0.018 and 0.05, p = 0.02). Renal dysfunction rate was significantly (p = 0.05) lower for diabetics in the HCC group (relative risk 0.28).

Conclusions: When HCCs were used postoperative times decreased and they had a protective effect on lung and kidney function in high-risk patients.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cardiopulmonary Bypass / instrumentation*
  • Diabetes Mellitus / physiopathology
  • Heparin / administration & dosage*
  • Humans
  • Intensive Care Units
  • Length of Stay
  • Lung Diseases, Obstructive / physiopathology
  • Middle Aged
  • Postoperative Complications
  • Prospective Studies
  • Risk Factors
  • Treatment Outcome

Substances

  • Heparin